Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06735833 · ClinicalTrials.gov registry record · NA
MMA Embolization for Refractory Chronic Migraine
A NA study of Migraine, sponsored by Cerenovus, Part of DePuy Synthes Products.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 7
- Study locations
NCT06735833: Recruiting NA study of Migraine, sponsored by Cerenovus, Part of DePuy Synthes Products.
NCT06735833 is a NA study of Migraine that is actively recruiting participants, run by Cerenovus, Part of DePuy Synthes Products. The registered enrollment target is 70 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06735833, a NA study of Migraine, is actively recruiting participants, sponsored by Cerenovus, Part of DePuy Synthes Products.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Conditions Studied
Interventions
- DEVICE Middle Meningeal Artery embolization
Study Locations (7)
New York
- University of Buffalo Medical Center - Buffalo
- Mount Sinai - New York
- Stony Brook University Medical Center - Stony Brook
Connecticut
- Hartford Hospital - Hartford
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Tennessee
- Semmes Murphey Foundation - Memphis
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2029-05-15 |
| Phase | NA |
What NCT06735833 shows while recruiting
NCT06735833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Middle Meningeal Artery embolization is the first listed.
NCT06735833 lists 7 locations in 5 states (New York, Connecticut, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06735833 about?
NCT06735833 is a clinical study titled "MMA Embolization for Refractory Chronic Migraine". This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
What is the current status of trial NCT06735833?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-04-23. Estimated completion is 2029-05-15.
What conditions does trial NCT06735833 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06735833?
The interventions under investigation include: Middle Meningeal Artery embolization (DEVICE).
Who is sponsoring clinical trial NCT06735833?
This trial is sponsored by Cerenovus, Part of DePuy Synthes Products, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06735833 being conducted?
This trial has 7 study locations across Connecticut, New York, Pennsylvania, Tennessee, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06735833's enrollment target sits among peer trials
70 71st of 102 higher than 32 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI